Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 369,721
  • Shares Outstanding, K 13,285
  • Annual Sales, $ 171,550 K
  • Annual Income, $ -8,630 K
  • 60-Month Beta 0.66
  • Price/Sales 2.10
  • Price/Cash Flow N/A
  • Price/Book 1.45
Trade EGRX with:

Options Overview Details

View History
  • Implied Volatility 73.18% ( +18.69%)
  • Historical Volatility 31.56%
  • IV Percentile 97%
  • IV Rank 77.47%
  • IV High 84.53% on 09/19/22
  • IV Low 34.13% on 11/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 1
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 2,736
  • Open Int (30-Day) 2,779

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.30
  • Number of Estimates 1
  • High Estimate 0.30
  • Low Estimate 0.30
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +169.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.21 +9.73%
on 09/22/22
35.90 -19.88%
on 08/29/22
-7.17 (-19.96%)
since 08/26/22
3-Month
26.21 +9.73%
on 09/22/22
47.71 -39.72%
on 07/06/22
-14.13 (-32.94%)
since 06/28/22
52-Week
26.21 +9.73%
on 09/22/22
58.25 -50.63%
on 10/04/21
-26.14 (-47.61%)
since 09/28/21

Most Recent Stories

More News
New Strong Sell Stocks for September 26th

EGRX, ACCO and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2022.

ACCO : 5.11 (+1.79%)
EGRX : 28.87 (+3.74%)
ATUS : 6.38 (+1.11%)
New Strong Sell Stocks for September 9th

EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.

TWTR : 43.17 (+2.57%)
EGRX : 28.87 (+3.74%)
PLAY : 31.85 (+2.21%)
New Strong Sell Stocks for September 1st

CCCS, BJRI and EGRX have been added to the Zacks Rank #5 (Strong Sell) List on September 1, 2022.

BJRI : 24.17 (+2.07%)
EGRX : 28.87 (+3.74%)
CCCS : 9.03 (+4.39%)
Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?

Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

MRK : 86.53 (+0.80%)
LLY : 339.10 (+9.00%)
EGRX : 28.87 (+3.74%)
BOLT : 1.5900 (-4.22%)
Eli Lilly's (LLY) Potential New Products Key to Growth

Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

BIIB : 270.99 (+37.01%)
LLY : 339.10 (+9.00%)
EGRX : 28.87 (+3.74%)
Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript

EGRX earnings call for the period ending June 30, 2022.

EGRX : 28.87 (+3.74%)
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EGRX : 28.87 (+3.74%)
LHDX : 1.1900 (+2.59%)
Eagle Pharmaceuticals Reports Second Quarter 2022 Results

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total...

EGRX : 28.87 (+3.74%)
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for...

EGRX : 28.87 (+3.74%)
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the...

MRVI : 25.15 (+0.20%)
EGRX : 28.87 (+3.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

3rd Resistance Point 28.86
2nd Resistance Point 28.39
1st Resistance Point 28.11
Last Price 28.87
1st Support Level 27.36
2nd Support Level 26.89
3rd Support Level 26.61

See More

52-Week High 58.25
Fibonacci 61.8% 46.01
Fibonacci 50% 42.23
Fibonacci 38.2% 38.45
Last Price 28.87
52-Week Low 26.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar